Diagnostics to rapidly screen individual patients for influenza virus in hospitals, clinics and doctors’ offices, personal protection devices such as facemasks to help stop the spread of disease,
The company has reported net revenues of $10.9 billion for the first quarter of 2009, a decrease of 8%, compared to $11.85 billion for the first quarter of
Net revenue for the fourth quarter of 2008 was $7.06 million, a decrease of 14.5% from $8.32 million for the fourth quarter of 2007. The decrease in net
Before joining PerkinElmer, Wilson was the corporate vice president of investor relations at Danaher Corporation (Danaher). At Danaher, he held key financial and business management positions. Wilson comes
“Rob’s leadership and deep understanding of PerkinElmer’s businesses, organization and entrepreneurial culture makes him ideally suited to lead the Company going forward,” said Summe. “I believe that PerkinElmer
Second Quarter Summary: Financial highlights: Operating income of $6.2 million Revenue by market: Therapeutic: Cardiovascular – $9.6 million Ophthalmology – $3.7 million Other Markets – $2.9 million Diagnostic
The main items in the report are: Highlights Operating profit improved by NOK16.7 million to NOK-5.7 million (NOK-22.5 million) Liquid funds amounted to NOK161.9 million at the end
Scott Garrett, chairman, president and chief executive officer, said, Approximately 80% of our revenue is recurring, which continued to grow at 5% on a constant currency basis giving
Recurring income increased 22.2% to JPY46.4 billion. Net income decreased by 50% to JPY11.7 billion, as extraordinary losses of JPY21.5 billion were recorded due to valuation losses on
Swiss biopharmaceutical company Actelion has reported that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has issued a positive opinion
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.